Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap
10.04.2026 10:50
Healthcare never sleeps.
Bristol Myers Squibb Cancer Alliance Adds Weight To Valuation Debate
10.04.2026 08:07
Bristol Myers Squibb (NYSE:BMY) announced a new multi year cancer immunotherapy partnership with Oxford BioTherapeutics. The collaboration focuses on developing novel T cell engager therapies for solid tumors using Oxford BioTherapeutics' proprietary platform. The agreement is structured as a multi year R&D alliance aimed at expanding Bristol Myers Squibb's oncology pipeline. Bristol Myers Squibb is a global biopharmaceutical company with a long standing focus on oncology and immunology,...
Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst
09.04.2026 03:14
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Blue Chip Stocks with Highest Dividends. On April 8, Cantor Fitzgerald raised the firm’s price recommendation on Bristol-Myers Squibb Company (NYSE:BMY) to $54 from $45. It reiterated a Neutral rating on the shares. The firm said it does not expect the Q1 earnings season to “dramatically […]
Guggenheim Reiterates Buy on Bristol-Myers Squibb, Maintains $72 Price Target
08.04.2026 09:02
Guggenheim analyst Seamus Fernandez reiterates Bristol-Myers Squibb (NYSE:BMY) with a Buy and maintains $72 price target.
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $54
08.04.2026 08:54
Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $45 to $54.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
06.04.2026 13:10
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
03.04.2026 13:40
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
01.04.2026 12:01
SAN DIEGO, April 01, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux’s TRACTr platform, targeting an undisclosed solid tumor antigen expres
Bristol Myers Squibb Evolves and Expands Standing in the Gaap To Advance More Equitable Care in Multiple Myeloma As Program Marks Ten Years
01.04.2026 11:29
New survey, guided by patient advocacy input, seeks to elevate lived experience and community voice to better understand challenges in multiple myeloma care PRINCETON, NJ / ACCESS Newswire / April 1, 2026 /Originally published by Bristol Myers Squibb ...
Janux Therapeutics Nominates Development Candidate Under Collaboration, License Agreement With Bristol Myers Squibb
01.04.2026 08:05
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
30.03.2026 07:34
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment
30.03.2026 06:07
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company’s combination treatment for adults and adolescents […]
Cobenfy Phase 4 Data May Reframe Bristol Myers Squibb Valuation Story
29.03.2026 16:06
Bristol Myers Squibb (NYSE:BMY) released Phase 4 trial data for Cobenfy in schizophrenia, focused on patients switching from other oral atypical antipsychotics. The results highlight safety and tolerability outcomes for Cobenfy, which combines xanomeline and trospium chloride. The data were presented at a major international congress as the first product-related update on switching since Cobenfy's approval. Bristol Myers Squibb, known primarily for its oncology and cardiovascular...
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
29.03.2026 15:45
PRINCETON, N.J., March 29, 2026--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM
Bristol-Myers Squibb Company (NYSE:BMY) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
29.03.2026 12:30
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
28.03.2026 11:15
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline. Right now, that diversification is being tested by two forces pulling in opposite directions: sweeping U.S. drug pricing policy and a dangerous level of concentration in one stock. The ... PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
28.03.2026 11:00
PRINCETON, N.J., March 28, 2026--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy.
Jim Cramer on Bristol-Myers Squibb: “The Stock’s Recent Pullbacks Have Represented Terrific Buying Opportunities”
27.03.2026 18:01
Jim Cramer reviewed Bristol-Myers Squibb Company (NYSE:BMY) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. Cramer explained why the Charitable Trust owns the stock, as he remarked: Finally, there’s Bristol-Myers. Okay, this is a stock I like so much that we own it for the Charitable Trust. It […]
Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
27.03.2026 18:01
Jim Cramer reviewed Pfizer Inc. (NYSE:PFE) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. Cramer mentioned the stock during the episode and said: In a slowdown, the hedge fund playbook says you want safety stocks. The stocks of companies that will make good money even if the broader […]
A Look At Bristol Myers Squibb (BMY) Valuation As Shares Show Mixed Recent Returns
27.03.2026 14:05
Why Bristol-Myers Squibb (BMY) is on investors’ radar now Bristol-Myers Squibb (BMY) shares recently closed at $59.43, with the stock showing mixed short term returns over the past week, month and past 3 months, which is prompting closer attention from investors. See our latest analysis for Bristol-Myers Squibb. The recent 1-day share price return of 0.83% and 7-day share price return of 2.27% sit against a 90-day share price return of 8.77% and year to date share price return of 11.17%. The...